HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Droxidopa

A precursor of noradrenaline that is used in the treatment of parkinsonism. The racemic form (DL-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a deficit of noradrenaline as well as of dopamine in Parkinson's disease and it has been proposed that this underlies the sudden transient freezing seen usually in advanced disease. Administration of DL-threo-3,4-dihydroxyphenylserine has been claimed to result in an improvement in this phenomenon but controlled studies have failed to demonstrate improvement. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)
Also Known As:
3,4-threo-DOPS; DL-threo-3,4-Dihydroxyphenylserine; Droxidopa, (DL-Tyr)-Isomer; erythro-3,4-Dihydroxyphenylserine; threo-DOPS; 3,4 Dihydroxyphenylserine; 3,4 threo DOPS; DL threo 3,4 Dihydroxyphenylserine; erythro 3,4 Dihydroxyphenylserine; threo DOPS; 3,4-Dihydroxyphenylserine; L-Tyrosine, beta,3-dihydroxy-, threo-
Networked: 84 relevant articles (19 outcomes, 11 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Hewitt, L Arthur: 5 articles (04/2015 - 01/2014)
2. Kaufmann, Horacio: 4 articles (01/2015 - 03/2008)
3. Biaggioni, Italo: 3 articles (01/2015 - 07/2014)
4. Mathias, Christopher J: 3 articles (01/2015 - 03/2008)
5. Ikemoto, Keiko: 3 articles (05/2004 - 08/2002)
6. Isaacson, Stuart: 2 articles (04/2015 - 01/2014)
7. Hauser, Robert A: 2 articles (04/2015 - 01/2014)
8. Freeman, Roy: 2 articles (01/2015 - 07/2014)
9. Low, Phillip: 2 articles (01/2015 - 07/2014)
10. Wang, Jingzhou: 1 article (10/2015)

Related Diseases

1. Orthostatic Hypotension (Postural Hypotension)
2. Parkinson Disease (Parkinson's Disease)
3. Dizziness (Lightheadedness)
07/22/2014 - "Improvement in OHQ symptom subscore favored droxidopa by 0.73 units (p = 0.010), with maximum change in "dizziness/lightheadedness." Improvement in symptom-impact subscore favored droxidopa by 1.06 units (p = 0.003), with maximum change for "standing a long time." Mean standing systolic blood pressure (BP) increased by 11.2 vs 3.9 mm Hg (p < 0.001), and mean supine systolic BP by 7.6 vs 0.8 mm Hg (p < 0.001). "
01/01/2014 - "At Week 1, mean dizziness/lightheadedness score change favored droxidopa by 1.5 units (p = 0.24), with subsequent numerical differences favoring droxidopa throughout the observation period, and at Week 1, mean standing systolic blood-pressure change favored droxidopa by 12.5 mmHg (p = 0.04). "
04/15/2015 - "For the initial 51 subjects (study nOH306A, previously reported), the primary efficacy measure, Orthostatic Hypotension Questionnaire (OHQ) composite score, did not demonstrate significant change versus placebo at maintenance week 8. For the subsequent 171 subjects (study nOH306B, reported here), the primary efficacy measure was change versus placebo on item 1 ("dizziness, lightheadedness, feeling faint, or feeling like you might black out") of the Orthostatic Hypotension Symptom Assessment (OHSA) subsection of the OHQ at maintenance week 1. At week 1, mean (standard deviation) improvement on OHSA item 1 was 2.3 (2.95) for droxidopa versus 1.3 (3.16) for placebo (P = 0.018). "
01/01/2015 - "Mean worsening of Orthostatic Hypotension Questionnaire dizziness/lightheadedness score from randomization to end of study (the primary outcome; N=101) was 1.9±3.2 with placebo and 1.3±2.8 units with droxidopa (P=0.509). "
04/15/2015 - "The most common AEs on droxidopa (vs. placebo) were headache (13.5% vs. 7.3%) and dizziness (10.1% vs. 4.9%). "
4. Tremor (Tremors)
5. Polyneuropathies (Polyneuropathy)

Related Drugs and Biologics

1. Norepinephrine (Noradrenaline)
2. Droxidopa
3. Levodopa (L Dopa)
4. Dopamine (Intropin)
5. Aromatic Amino Acids (Aromatic Amino Acid)
6. Dopa Decarboxylase
7. Atrial Natriuretic Factor (ANF)
8. Serotonin (5 Hydroxytryptamine)
9. P-300
10. Midodrine (Midon)

Related Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Activities of Daily Living (ADL)
3. Injections
4. Aftercare (After-Treatment)
5. Oral Administration